FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Brewis Neil
2. Issuer Name and Ticker or Trading Symbol

F-star Therapeutics, Inc. [ FSTX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Scientific Officer
(Last)          (First)          (Middle)

C/O F-STAR THERAPEUTICS, INC., EDDEVA B920, BABRAHAM RESEARCH CAMPUS
3. Date of Earliest Transaction (MM/DD/YYYY)

1/9/2022
(Street)

CAMBRIDGE, X0 CB22 3AT
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) $4.77 1/9/2022  A   74263 (1)    (2)1/9/2032 Common Stock 74263 $0.00 74263 D  

Explanation of Responses:
(1) These options were granted under the Issuer's 2019 Equity Incentive Plan.
(2) Twenty five percent (25%) of the total number of shares under the award shall vest on the first anniversary of the Vesting Commencement Date, January 9, 2022, and thereafter in 36 equal monthly installments such that the stock option shall be fully-vested on the fourth annual anniversary of the Vesting Commencement Date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Brewis Neil
C/O F-STAR THERAPEUTICS, INC.
EDDEVA B920, BABRAHAM RESEARCH CAMPUS
CAMBRIDGE, X0 CB22 3AT


Chief Scientific Officer

Signatures
/s/ Darlene Deptula-Hicks, Attorney-in-fact1/11/2022
**Signature of Reporting PersonDate

F star Therapeutics (NASDAQ:FSTX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more F star Therapeutics Charts.
F star Therapeutics (NASDAQ:FSTX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more F star Therapeutics Charts.